The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology
T Kubo,K Sunami,T Koyama,M Kitami,Y Fujiwara,S Kondo,K Yonemori,E Noguchi,C Morizane,Y Goto,A Maejima,S Iwasa,T Hamaguchi,A Kawai,K Namikawa,A Arakawa,M Sugiyama,M Ohno,T Yoshida,N Hiraoka,A Yoshida,M Yoshida,T Nishino,E Furukawa,D Narushima,M Nagai,M Kato,H Ichikawa,Y Fujiwara,T Kohno,N Yamamoto,T. Kubo,K. Sunami,T. Koyama,M. Kitami,Y. Fujiwara,S. Kondo,K. Yonemori,E. Noguchi,C. Morizane,Y. Goto,A. Maejima,S. Iwasa,T. Hamaguchi,A. Kawai,K. Namikawa,A. Arakawa,M. Sugiyama,M. Ohno,T. Yoshida,N. Hiraoka,A. Yoshida,M. Yoshida,T. Nishino,E. Furukawa,D. Narushima,M. Nagai,M. Kato,H. Ichikawa,Y. Fujiwara,T. Kohno,N. Yamamoto
DOI: https://doi.org/10.1016/j.esmoop.2024.102981
IF: 6.883
2024-04-14
ESMO Open
Abstract:Of 507 patients who underwent CGP, 12.2% received genomically matched therapies with a 32.3% ORR. The PFS ratios (>1.3) were observed in 46.3% (19/41) of the evaluated patients. Patients with rare cancers benefited most from tumor mutation profiling. Early-line treatments following profiling increase the therapeutic benefit, irrespective of tumor type. Comprehensive genome profiling (CGP) serves as a guide for suitable genomically matched therapies for patients with cancer. However, little is known about the impact of the timing and types of cancer on the therapeutic benefit of CGP. A single hospital-based pan-cancer prospective study (TOP-GEAR; UMIN000011141) was conducted to examine the benefit of CGP with respect to the timing and types of cancer. Patients with advanced solid tumors (>30 types) who either progressed with or without standard treatments were genotyped using a single CGP test. The subjects were followed up for a median duration of 590 days to examine therapeutic response, using progression-free survival (PFS), PFS ratio, and factors associated with therapeutic response. Among the 507 patients, 62 (12.2%) received matched therapies with an overall response rate (ORR) of 32.3%. The PFS ratios (≥1.3) were observed in 46.3% (19/41) of the evaluated patients. The proportion of subjects receiving such therapies in the rare cancer cohort was lower than that in the non-rare cancer cohort (9.6% and 17.4%, respectively; P = 0.010). However, ORR of the rare cancer patients was higher than that in the non-rare cancer cohort (43.8% and 20.0%, respectively; P = 0.046). Moreover, ORR of matched therapies in the first or second line after receiving the CGP test was higher than that in the third or later lines (62.5% and 21.7%, respectively; P = 0.003). Rare cancer and early-line treatment were significantly and independently associated with ORR of matched therapies in multivariable analysis ( P = 0.017 and 0.004, respectively). Patients with rare cancer preferentially benefited from tumor mutation profiling by increasing the chances of therapeutic response to matched therapies. Early-line treatments after profiling increase the therapeutic benefit, irrespective of tumor types.
oncology